Document Detail


Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
MedLine Citation:
PMID:  17461849     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of the study was to assess the frequency of the concurrent use of gastric acid-reducing agents among HIV-1-infected patients treated with highly active antiretroviral therapy (HAART) combinations. METHODS: An anonymous, semistructured, self-administered questionnaire was consecutively distributed among HIV-1-infected patients at routine visits to specialized HIV clinics. The questionnaire contained 17 items asking specifically for information on current antiretroviral treatments and the use of gastric acid-reducing agents as well as demographic data. RESULTS: A total of 424 patients in 12 centres participated in the study: 85% were male, 88% were of German nationality, 82% were >35 years of age and 201 (47.4%) were receiving a protease inhibitor (PI)-containing HAART regimen. Of these, 74 (37%) had received an acid-reducing drug within the previous 6 months and 43 (58%) were currently still on it. Two-thirds of patients (64.9%) were treated with proton-pump inhibitors (pantoprazole, omeprazole or esomeprazole) and 56% of patients on PI-containing regimens had been taking these drugs for longer than 2 months and up to a maximum of 3 years. The majority of patients (77%) had received the prescription for the acid-reducing drugs from their HIV specialist and the remaining patients had received over the counter (OTC) medication or prescriptions from other medical personnel. CONCLUSIONS: A substantial subset of patients treated with HAART combinations, including those on PI-containing regimens, were using concomitant acid-reducing drugs, most often proton-pump inhibitors. As negative drug-drug interactions between some of the (boosted) PIs and gastric acid-reducing agents have recently been reported, HIV physicians should take this into account when prescribing PI-containing HAART combinations in order to avoid an additional risk of treatment failure.
Authors:
J van Lunzen; H Liess; K Arastéh; R Walli; B Daut; D Schürmann
Related Documents :
8605279 - Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b.
7706829 - Immunochemotherapy for a systemic intracellular infection: accelerated response using i...
12201869 - Combination therapy for children with chronic hepatitis b virus infection.
18384519 - Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin fo...
15980689 - Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combi...
17760739 - Prior antiretroviral therapy experience protects against zidovudine-related anaemia.
1738729 - Total ankle joint replacement: a clinical follow up.
2678499 - Repair of pectus excavatum using a substernal metal strut within a marlex envelope.
17627979 - Supra-tenon's capsule placement of a single-plate molteno implant.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  HIV medicine     Volume:  8     ISSN:  1464-2662     ISO Abbreviation:  HIV Med.     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-04-27     Completed Date:  2007-12-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897392     Medline TA:  HIV Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  220-5     Citation Subset:  IM    
Affiliation:
University Medical Center Hamburg--Eppendorf, Infectious Diseases Unit, Hamburg, Germany. v.lunzen@uke.uni-hamburg.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Antacids / therapeutic use*
Antiretroviral Therapy, Highly Active / methods*
Drug Interactions
Female
HIV Infections / drug therapy*
HIV Protease Inhibitors / therapeutic use*
HIV-1 / growth & development*
Humans
Male
Middle Aged
Proton Pump Inhibitors / therapeutic use*
Questionnaires
Chemical
Reg. No./Substance:
0/Antacids; 0/HIV Protease Inhibitors; 0/Proton Pump Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients car...
Next Document:  Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containin...